08048035968
Premium Exporter of Genuine PEG L-ASPATERO 3750IU/5ml from India to Singapore –Orchard| Phoenix Exim

1. General Information

PEG L-Aspatero 3750 IU/5 mL Injection is an injectable formulation containing PEGylated L-asparaginase. It belongs to the antineoplastic class of medicines and is mainly used in chemotherapy protocols for acute lymphoblastic leukemia. The medicine reduces the availability of asparagine in the blood, an amino acid that leukemia cells depend on for protein synthesis and survival.

For pharmaceutical supply and export inquiries, Phoenix Exim, Nagpur, India supplies medicines for international markets including the USA, UK, Australia, Singapore, Canada, South Korea, and UAE, subject to applicable regulatory requirements.

2. Product Information

  • Product: PEG L-Aspatero Injection
  • Strength: 3750 IU/5 mL
  • Active ingredient: PEGylated L-asparaginase / Pegaspargase
  • Dosage form: Injection
  • Pack: 5 mL vial
  • Therapeutic class: Antineoplastic
  • Primary indication: Acute lymphoblastic leukemia (ALL)
  • Administration: Intramuscular (IM) or intravenous (IV), according to the prescribed treatment protocol
  • Storage: Refrigerate at 2°C–8°C and do not freeze.

3. Uses of PEG L-Aspatero 3750 IU/5 mL Injection

PEG L-Aspatero is primarily used in the treatment of acute lymphoblastic leukemia (ALL). It may be incorporated into combination chemotherapy regimens and can be particularly useful when asparaginase therapy is required.

Its use, dose, frequency, and treatment duration are determined by the patient's chemotherapy protocol and treating oncologist.

4. Benefits of This Medicine

The major therapeutic benefit of PEG L-Aspatero is its ability to deplete asparagine from the bloodstream. Leukemia cells may have limited ability to produce sufficient asparagine themselves, making them more dependent on circulating asparagine. By breaking down circulating asparagine, pegylated L-asparaginase can interfere with leukemia-cell protein production and contribute to cancer-cell death.

PEGylation also provides prolonged activity compared with conventional L-asparaginase formulations, allowing dosing according to established chemotherapy protocols.

5. Side Effects of PEG L-Aspatero

Possible adverse effects include:

  • Allergic or hypersensitivity reactions
  • Nausea and vomiting
  • Diarrhea
  • Fatigue
  • Fever
  • Rash or hives
  • Dizziness
  • Increased blood glucose
  • Changes in liver enzymes
  • Low blood pressure
  • Edema
  • Decreased albumin levels

More serious complications can include pancreatitis, liver toxicity, blood clots, and serious bleeding. Severe allergic reactions can also occur and require immediate medical attention.

6. Common Side Effects

Some commonly reported effects include:

  1. Nausea
  2. Vomiting
  3. Diarrhea
  4. Fatigue or tiredness
  5. Fever
  6. Rash
  7. Breathlessness
  8. Dizziness
  9. Increased blood glucose
  10. Increased liver enzymes
  11. Swelling/edema
  12. Low blood pressure

Patients should inform their healthcare team if symptoms are persistent, severe, or worsening.

7. How to Use PEG L-Aspatero

PEG L-Aspatero should only be administered by a doctor, nurse, or other qualified healthcare professional. It should not be self-injected. The prescribed dose and route depend on the patient's age, body size, diagnosis, chemotherapy protocol, and clinical condition.

Before administration, the healthcare team should review relevant medical history and monitor the patient according to the chemotherapy protocol.

8. How PEG L-Aspatero Works

PEG L-Aspatero contains pegylated L-asparaginase. The enzyme breaks down L-asparagine in the bloodstream into its metabolic products. Leukemia cells can depend on extracellular asparagine because they may not produce enough of it to meet their needs.

Reducing circulating asparagine interferes with protein synthesis in susceptible leukemia cells, which can inhibit their growth and ultimately contribute to their death.

9. Safety Advice

  • Use only under the supervision of a qualified oncology team.
  • Tell your doctor about any previous allergic reaction to asparaginase or pegaspargase.
  • Inform the doctor about previous or existing pancreatitis, liver problems, blood clots, or bleeding disorders.
  • Blood glucose, liver function, coagulation parameters and other relevant laboratory values may need regular monitoring.
  • Seek urgent medical attention for severe allergic symptoms, significant abdominal pain, unusual bleeding, chest pain, breathing difficulty, or symptoms suggestive of a blood clot.
  • Inform your doctor about all prescription medicines, over-the-counter medicines, and supplements you use.
  • Discuss pregnancy, plans for pregnancy, or breastfeeding with your healthcare professional before treatment.
  • Store refrigerated at 2°C–8°C and protect the product according to the manufacturer's storage instructions; do not freeze.

10. FAQs

Q1. What is PEG L-Aspatero 3750 IU/5 mL Injection used for?
It is primarily used as part of chemotherapy treatment for acute lymphoblastic leukemia (ALL).

Q2. What is the active ingredient?
It contains PEGylated L-asparaginase, also known as pegaspargase.

Q3. Can PEG L-Aspatero be self-administered?
No. It should be administered by a qualified healthcare professional.

Q4. How should it be stored?
It should generally be stored refrigerated at 2°C–8°C and should not be frozen.

Q5. Can PEG L-Aspatero cause high blood sugar?
Yes. Increased blood glucose can occur, so monitoring may be required during treatment.

Q6. Can it cause pancreatitis?
Yes. Pancreatic complications are recognized with asparaginase-based treatment. Severe or persistent abdominal pain should be reported immediately to the treating physician.

Q7. Can children receive PEG L-Aspatero?
Asparaginase-based treatment is used in pediatric ALL protocols, but dosing must be determined by the treating oncology team based on the individual patient and treatment protocol.

Q8. Is PEG L-Aspatero a prescription medicine?
Yes. It is a prescription anticancer medicine and should be used only under appropriate medical supervision.

11. Substitutes for PEG L-Aspatero 3750 IU/5 mL

Potential alternatives include other pegylated L-asparaginase/pegaspargase products, such as products marketed under different brand names. Examples identified in Indian pharmaceutical listings include Peg L-Aparagin 3750 IU Injection and other PEG-asparaginase formulations.

Important: A substitute should not be selected solely by brand name or strength. The treating oncologist should confirm the appropriate formulation, dose, route, and chemotherapy protocol.

12. SEO Keywords

Primary keywords:

  • PEG L-Aspatero 3750 IU Injection
  • PEG L-Aspatero 3750 IU/5 mL Injection
  • PEG L-Aspatero Injection
  • PEG L-Aspatero 3750 IU
  • Pegaspargase 3750 IU Injection
  • PEGylated L-asparaginase Injection
  • L-Asparaginase 3750 IU Injection
  • Acute Lymphoblastic Leukemia Injection

Long-tail B2B/export keywords:

  • PEG L-Aspatero 3750 IU Injection exporter from India
  • PEG L-Aspatero 3750 IU Injection supplier from Nagpur India
  • PEG L-Aspatero 3750 IU/5 mL Injection exporter
  • Pegaspargase Injection pharmaceutical exporter India
  • PEGylated L-asparaginase Injection supplier India
  • PEG L-Aspatero Injection wholesale supplier
  • PEG L-Aspatero 3750 IU Injection for international supply
  • Acute lymphoblastic leukemia medicines exporter from India
  • Oncology injection exporter from Nagpur India
  • PEG L-Aspatero 3750 IU Injection supplier for USA
  • PEG L-Aspatero 3750 IU Injection supplier for UK
  • PEG L-Aspatero 3750 IU Injection supplier for Australia
  • PEG L-Aspatero 3750 IU Injection supplier for Singapore
  • PEG L-Aspatero 3750 IU Injection supplier for Canada
  • PEG L-Aspatero 3750 IU Injection supplier for South Korea
  • PEG L-Aspatero 3750 IU Injection supplier for UAE
Aug 20th, 2026 2:08 PM

Keywords